Sham Comparator

Preclinical

Sanofi

Sham Comparator is one of 33 therapeutic programs targeting Geographic Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Geographic AtrophyRecruiting

Geographic AtrophyPreclinical

Recruiting

Competition

Competitive Landscape

38 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Empaveli

Apellis Pharmaceuticals

Phase 3

3 5

Cemdisiran

Tecfidera

1 7

Farxiga

AstraZeneca

Phase 2

1 8

Xylocaine

MMEDRx USA, Inc.

Phase 2

1 9

Rapamune

PPrism Pharmaceuticals

Phase 2

1 10

Glucophage

EMD Serono

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

PreclinicalRecruiting

Geographic Atrophy

NCT07215234

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT07215234·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sham Comparator. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sham Comparator. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Sanofi

Sham Comparator

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Geographic Atrophy1 trial

References

Drug Info

Quick Facts

Related News